Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis

References

• AlamanosYVoulgariPVDrososAAIncidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic reviewSemin Arthritis Rheum200636318218817045630
   PubMed Web of Science ®Google Scholar
• GabrielSEMichaudKEpidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseasesArthritis Res Ther200911322919519924
   PubMed Web of Science ®Google Scholar
• KeystoneECSmolenJvan RielPDeveloping an effective treatment algorithm for rheumatoid arthritisRheumatology (Oxford)201251Suppl 5v48v5422718927
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnn Rheum Dis201069696497520444750
   PubMed Web of Science ®Google Scholar
• ChoyEHKavanaughAFJonesSAThe problem of choice: current biologic agents and future prospects in RANat Rev Rheumatol20139315416323419427
   PubMed Web of Science ®Google Scholar
• SinghJAFurstDEBharatA2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res (Hoboken)201264562563922473917
   PubMed Web of Science ®Google Scholar
• PierreisnardAIssaNBarnetcheTRichezCSchaeverbekeTMeta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexateJoint Bone Spine201380438639223141718
   PubMed Web of Science ®Google Scholar
• AaltonenKJVirkkiLMMalmivaaraAKonttinenYTNordströmDCBlomMSystematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritisPLoS One201271e3027522272322
   PubMed Web of Science ®Google Scholar
• HetlandMLChristensenIJTarpUAll Departments of Rheumatology in DenmarkDirect comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registryArthritis Rheum2010621223220039405
   PubMed Web of Science ®Google Scholar
• MontgomeryAAFaheyTHow do patients’ treatment preferences compare with those of clinicians?Qual Health Care200110Suppl 1i39i4311533437
   PubMedGoogle Scholar
• YaziciYMcMorrisBJDarkowTRosenblattLCPatient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritisClin Exp Rheumatol200927690791320149304
   PubMed Web of Science ®Google Scholar
• PullarTWrightVFeelyMWhat do patients and rheumatologists regard as an ‘acceptable’ risk in the treatment of rheumatic disease?Br J Rheumatol19902932152182357506
   PubMedGoogle Scholar
• van HulstLTKievitWvan BommelRvan RielPLFraenkelLRheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experimentArthritis Care Res (Hoboken)201163101407141421748861
   PubMed Web of Science ®Google Scholar
• KennedyTMcCabeCStruthersGBritish Society for Rheumatology Standards, Guidelines and Audit Working Group (SGAWG)BSR guidelines on standards of care for persons with rheumatoid arthritisRheumatology (Oxford)200544455355615728419
   PubMed Web of Science ®Google Scholar
• KirwanJRHewlettSEHeibergTIncorporating the patient perspective into outcome assessment in rheumatoid arthritis – progress at OMERACT 7J Rheumatol200532112250225616265712
   PubMedGoogle Scholar
• ScarpatoSAntivalleMFavalliEGRIVIERA co-authorsPatient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)Rheumatology (Oxford)201049228929419920093
   PubMed Web of Science ®Google Scholar
• WilliamsELEdwardsCJPatient preferences in choosing anti-TNF therapies-R1Rheumatology (Oxford)200645121575157617085468
   PubMed Web of Science ®Google Scholar
• ChiltonFCollettRATreatment choices, preferences and decision-making by patients with rheumatoid arthritisMusculoskeletal Care20086111417726671
   PubMedGoogle Scholar
• FraenkelLFriedTRIndividualized medical decision making: necessary, achievable, but not yet attainableArch Intern Med2010170656656920308644
   PubMedGoogle Scholar
• FraenkelLMcGrawSWhat are the essential elements to enable patient participation in medical decision making?J Gen Intern Med200722561461917443368
   PubMed Web of Science ®Google Scholar
• Cunha-MirandaLCostaLRibeiroJSNEAR study: Needs and Expectations in Rheumatoid ARthritis – do we know our patients needs?Acta Reumatol Port201035331432320975634
   PubMed Web of Science ®Google Scholar
• HoMLaveryBPullarTThe risk of treatment. A study of rheumatoid arthritis patients’ attitudesBr J Rheumatol19983744594609619900
   PubMedGoogle Scholar
• MarshallNJWilsonGLapworthKKayLJPatients’ perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative studyRheumatology (Oxford)20044381034103815150436
   PubMed Web of Science ®Google Scholar
• Goekoop-RuitermanYPde Vries-BouwstraJKAllaartCFPatient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial)Ann Rheum Dis20076691227123217405834
   PubMed Web of Science ®Google Scholar
• MartinRWHeadAJRenéJPatient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physicianJ Rheumatol200835461862418278840
   PubMed Web of Science ®Google Scholar
• CurtisJRChenLHarroldLRNarongroeknawinPReedGSolomonDHPhysician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activityArthritis Care Res (Hoboken)201062110110720191497
   PubMed Web of Science ®Google Scholar